215 related articles for article (PubMed ID: 30016770)
1. Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease.
Butterworth RF; Canbay A
Dig Dis; 2019; 37(1):63-68. PubMed ID: 30016770
[TBL] [Abstract][Full Text] [Related]
2. L-Ornithine L-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease.
Canbay A; Sowa JP
Drugs; 2019 Feb; 79(Suppl 1):39-44. PubMed ID: 30706422
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy.
Kircheis G; Lüth S
Drugs; 2019 Feb; 79(Suppl 1):23-29. PubMed ID: 30706424
[TBL] [Abstract][Full Text] [Related]
4. Effect of L-ornithine-L-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial.
Rees CJ; Oppong K; Al Mardini H; Hudson M; Record CO
Gut; 2000 Oct; 47(4):571-4. PubMed ID: 10986219
[TBL] [Abstract][Full Text] [Related]
5. Ornithine Aspartate and Vitamin-E Combination Has Beneficial Effects on Cardiovascular Risk Factors in an Animal Model of Nonalcoholic Fatty Liver Disease in Rats.
de Freitas LBR; Longo L; Filippi-Chiela E; de Souza VEG; Behrens L; Pereira MHM; Leonhard LC; Zanettini G; Pinzon CE; Luchese E; Lima GJSP; Cerski CT; Uribe-Cruz C; Álvares-da-Silva MR
Biomolecules; 2022 Nov; 12(12):. PubMed ID: 36551202
[TBL] [Abstract][Full Text] [Related]
6. l-Ornithine-l-Aspartate (LOLA) Normalizes Metabolic Parameters in Models of Steatosis, Insulin Resistance and Metabolic Syndrome.
Canbay A; Götze O; Kucukoglu O; Weinert S; Croner RS; Baars T; Özçürümez MK; Gieseler RK
Pharmaceutics; 2024 Apr; 16(4):. PubMed ID: 38675168
[TBL] [Abstract][Full Text] [Related]
7. Impact of L-ornithine L-aspartate on non-alcoholic steatohepatitis-associated hyperammonemia and muscle alterations.
Pichon C; Nachit M; Gillard J; Vande Velde G; Lanthier N; Leclercq IA
Front Nutr; 2022; 9():1051157. PubMed ID: 36466421
[TBL] [Abstract][Full Text] [Related]
8. L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses.
Butterworth RF; McPhail MJW
Drugs; 2019 Feb; 79(Suppl 1):31-37. PubMed ID: 30706425
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy.
Blanco Vela CI; Poo Ramírez JL
Ann Hepatol; 2011 Jun; 10 Suppl 2():S55-9. PubMed ID: 22228883
[TBL] [Abstract][Full Text] [Related]
10. [Aspartate-ornithine granules in the treatment of nonalcoholic steatohepatitis: a multiple-dose parallel controlled clinical trial].
Tian LY; Lu LG; Tang CW; Xie Y; Luo HS; Tan SY; Pang Z; Zhang YL; Gong LB; Li YM; Chen SH; Shi JP
Zhonghua Gan Zang Bing Za Zhi; 2013 Jul; 21(7):528-32. PubMed ID: 24074713
[TBL] [Abstract][Full Text] [Related]
11. Preventive effects of citrulline on Western diet-induced non-alcoholic fatty liver disease in rats.
Jegatheesan P; Beutheu S; Freese K; Waligora-Dupriet AJ; Nubret E; Butel MJ; Bergheim I; De Bandt JP
Br J Nutr; 2016 Jul; 116(2):191-203. PubMed ID: 27197843
[TBL] [Abstract][Full Text] [Related]
12. L-Aspartate, L-Ornithine and L-Ornithine-L-Aspartate (LOLA) and Their Impact on Brain Energy Metabolism.
Das A; Fröhlich D; Achanta LB; Rowlands BD; Housley GD; Klugmann M; Rae CD
Neurochem Res; 2020 Jun; 45(6):1438-1450. PubMed ID: 32424601
[TBL] [Abstract][Full Text] [Related]
13. Intravenous versus oral 'L-ornithine-L-aspartate' in overt hepatic encephalopathy: a randomized comparative study.
Jhajharia A; Singh S; Jana S; Ashdhir P; Nijhawan S
Sci Rep; 2024 May; 14(1):11862. PubMed ID: 38789596
[TBL] [Abstract][Full Text] [Related]
14. L-Ornithine L-Aspartate for the Treatment of Sarcopenia in Chronic Liver Disease: The Taming of a Vicious Cycle.
Butterworth RF
Can J Gastroenterol Hepatol; 2019; 2019():8182195. PubMed ID: 31183339
[TBL] [Abstract][Full Text] [Related]
15. Investigation into the antioxidant role of arginine in the treatment and the protection for intralipid-induced non-alcoholic steatohepatitis.
Abu-Serie MM; El-Gamal BA; El-Kersh MA; El-Saadani MA
Lipids Health Dis; 2015 Oct; 14():128. PubMed ID: 26463841
[TBL] [Abstract][Full Text] [Related]
16. Hepatoprotective and antioxidant effects of lycopene on non-alcoholic fatty liver disease in rat.
Jiang W; Guo MH; Hai X
World J Gastroenterol; 2016 Dec; 22(46):10180-10188. PubMed ID: 28028366
[TBL] [Abstract][Full Text] [Related]
17. Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS.
Bai M; He C; Yin Z; Niu J; Wang Z; Qi X; Liu L; Yang Z; Guo W; Tie J; Bai W; Xia J; Cai H; Wang J; Wu K; Fan D; Han G
Aliment Pharmacol Ther; 2014 Jul; 40(1):63-71. PubMed ID: 24832463
[TBL] [Abstract][Full Text] [Related]
18. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
[TBL] [Abstract][Full Text] [Related]
19. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
20. Effect of resveratrol on experimental non-alcoholic steatohepatitis.
Heebøll S; Thomsen KL; Clouston A; Sundelin EI; Radko Y; Christensen LP; Ramezani-Moghadam M; Kreutzfeldt M; Pedersen SB; Jessen N; Hebbard L; George J; Grønbæk H
Pharmacol Res; 2015; 95-96():34-41. PubMed ID: 25814186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
